Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Vistagen reported a fiscal 2026 net loss of $69.7 million, or $(1.83) per share, compared to a net loss of $51.4 million in the prior year, as R&D expenses increased to support the PALISADE program. The company ended the period with $45.4 million in cash, sufficient to fund operations into 2027, and completed the randomized portion of its Phase 3 PALISADE-4 trial for fasedienol, with topline data expected later this month.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.